The Effect of Chronic Trimetazidine Administration on Left Ventricular Function and Quality Of Life in Libyan Patients with Heart Failure
Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2017, Vol 1, Issue 1
Abstract
Background: Heart failure is a major cardiovascular disease and public health problem. It is complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of the blood. Trimetazidine is a cardio-protective drug that exerts cytoprotective effects by inhibition of the mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Aim: This study was aimed to examine effects of chronic trimetazidine administration on left ventricular function, symptoms and quality of life of patients with heart failure (secondary to ischemic or non-ischemic heart disease). Methods: This study was conducted at Cardiology unit of Tripoli Medical Center on 46 Libyan patients (39 - 85 years, 27 men : 19 women) diagnosed with chronic heart failure due to ischemic or non-ischemic heart diseases. The patients received, in addition to the standard therapy of heart failure, 35 mg of trimetazidine twice per day for six months. Patients were evaluated for left ventricular function by echocardiography after six months of the therapy. Symptoms and quality of life were assessed by Minnesota questionnaire after six months of trimetazidine use. Results: The mean of left ventricular ejection fraction before treatment with trimetazidine was 37.9% and after treatment was 40.6%. The mean of left ventricular end diastolic diameter before treatment with trimetazidine was 63.544 mm and after treatment was 62.261 mm. Trimetazidine therapy was associated with a considerable improvement in left ventricular ejection fraction (p < 0.05) and a significant decrease in left ventricular end diastolic diameter (p < 0.05). There was no improvement in symptoms and quality of life of heart failure patients on trimetazidine therapy. Conclusion: Treatment with trimetazidine for six months with the conventional heart failure drugs improves the left ventricular function.
Authors and Affiliations
Narges A Albibas, Osama A Bheleel, Fathi M Sherif
Keywords
Related Articles
- EP ID EP567408
- DOI 10.26717/BJSTR.2017.01.000135
- Views 175
- Downloads 0
Propagation of S. aureus Phage K in Presence of Human Blood
Bacteriophage (phage) treatment has proven successful for the treatment of bacteremia caused by Staphylococcus aureus (SA). Surprisingly, a recent study shows that blood inhibits SA phage propagation in vitro. Here we in...
Flapless Dental Implant: Contemporary Trends in Literature Coverage
The past decade in medicine it has been established the concept of minimally invasive surgery, consisting in taking advantage of advancements experienced in diagnostic techniques and specific surgical instruments, to per...
Sustainable Development Behavior in the Eco-Label Business Community
Changing market mechanisms by focusing on clean technologies and reducing the consumption of nonrenewable resources is an objective of the Europe 2020 strategy of the European Commission. Achieving this objective will re...
A New Perspective of Agroecosystem in 21st Century
Land is a living legend, including all eroded and forest land that all would contribute to agriculture. In a wider perspective, a long-term view will have to be taken to manage our soil, plant and bio-resources. Sustaina...
Laparoscopic Removal of Intra Abdominal MigratedIntrauterine Device Involved in the Omentum
Background: The presence of an intrauterine device migrated into the abdominal cavity can be detected incidentally or due to complications (the most frequent abdominal pain, obstructive 8complications or cause of acute a...